ATNM-400
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Key Facts
About Actinium Pharmaceuticals
Actinium Pharmaceuticals is a clinical-stage biotech company focused on developing targeted radiotherapies using its proprietary Actinium-225 (Ac-225) technology platform. Its mission is to deliver potent, precise radiation directly to cancer cells, with a pipeline spanning targeted conditioning for bone marrow transplant (Iomab-B), therapies for hematologic cancers (Actimab-A), and a multi-indication solid tumor candidate (ATNM-400). The company's strategy leverages its deep intellectual property in Ac-225 manufacturing and conjugation to create first-in-class therapies, funded through equity offerings and strategic partnerships like its $35M upfront deal with Immedica for Iomab-B.
View full company profileAbout Actinium Pharmaceuticals
Actinium Pharmaceuticals is a clinical-stage biotech company focused on developing targeted radiotherapies using its proprietary Actinium-225 (Ac-225) technology platform. Its mission is to deliver potent, precise radiation directly to cancer cells, with a pipeline spanning targeted conditioning for bone marrow transplant (Iomab-B), therapies for hematologic cancers (Actimab-A), and a multi-indication solid tumor candidate (ATNM-400). The company's strategy leverages its deep intellectual property in Ac-225 manufacturing and conjugation to create first-in-class therapies, funded through equity offerings and strategic partnerships like its $35M upfront deal with Immedica for Iomab-B.
View full company profileAbout Actinium Pharmaceuticals
Actinium Pharmaceuticals is a clinical-stage biotech company focused on developing targeted radiotherapies using its proprietary Actinium-225 (Ac-225) technology platform. Its mission is to deliver potent, precise radiation directly to cancer cells, with a pipeline spanning targeted conditioning for bone marrow transplant (Iomab-B), therapies for hematologic cancers (Actimab-A), and a multi-indication solid tumor candidate (ATNM-400). The company's strategy leverages its deep intellectual property in Ac-225 manufacturing and conjugation to create first-in-class therapies, funded through equity offerings and strategic partnerships like its $35M upfront deal with Immedica for Iomab-B.
View full company profileTherapeutic Areas
Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs
| Drug | Company | Phase |
|---|---|---|
| Tomivosertib | eFFECTOR Therapeutics | Phase 2 |
| Gedatolisib + Darolutamide | Celcuity | Phase 1b/3 |
| SNP-101 (estimated) | SmartNuclide Biopharma | Phase 1 |
| AB001 (²¹²Pb-NG001) | ARTBIO | Phase 1/2 |
| AB-3028 | Arsenal Biosciences | IND-Enabling |
| PRO CAR-201A | PromiCell | Phase 1 |
| PRO CAR-202 | PromiCell | Preclinical |
| FG-3246 | Kyntra Bio | Phase 2 |
| PROVENGE (sipuleucel-T) | Dendreon | Approved |
| RP12146 | Rhizen Pharmaceuticals | Phase 1b |
| Monoclonal Antibody (undisclosed) | MetaCurUm Biotech | Preclinical |
| ModraDoc006/r | Modra Pharmaceuticals | Phase 2b |